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The purpose of this study was to identify attitudes toward HPV vaccination among US women 27 to 45 years of age. A survey was
mailed to 2,750 insured US women to assess perceptions of relevance or irrelevance of the HPV vaccine, the underlying reasons,
and, for those reporting relevance, the likelihood of vaccination if it became available. Among the 451 eligible respondents, 304
(67.4%) reported that the HPV vaccine was relevant to them, whereas 143 (31.7%) stated that it was not at all relevant. The
most common reasons for relevance were protection from cervical cancer (62.8%), vaginal cancer (58.2%), precancerous cells
(55.9%), HPV (55.6%), and genital warts (46.4%). Reasons for irrelevance were most commonly being married (54.0%) or in a
monogamous relationship (39.6%). Most respondents reporting relevance of the HPV vaccine were likely (33.4%) or extremely
likely (37.7%) to receive the vaccine if approved for their age group.
1.Introduction
Human papillomavirus (HPV) is the most common sexually
transmitted infection in the United States [1]. Low-risk HPV
types 6 and 11 cause 90% of cases of genital warts, while
high-risk HPV types 16 and 18 are responsible for 70% of
cervical cancers and also cause cancers of the anus, vagina,
vulva, and head and neck [2, 3]. As of 2004, the prevalence
of HPV infection was 26.8% among US women aged 14–59
[4]. A gradual decline in prevalence with age is apparent in
women in their ﬁfties (19.6%) compared to those in their
forties (25.2%) and thirties (27.5%) [4].
Two HPV vaccines are licensed in the United States.
A quadrivalent vaccine targeting HPV types 6, 11, 16, and
18 was approved in 2006 for females aged 9–26 [5], and
a bivalent vaccine targeting types 16 and 18 was approved in
2009 for females aged 10–25 [6]. The US Advisory Commit-
tee on Immunization Practices (ACIP) recommends routine
vaccination of girls aged 11-12 and catch-up vaccination of
females aged 13–26 with either vaccine [7]. Both vaccines
have been studied in women over 26 [8, 9] and are approved
or under regulatory review in several countries for use in
older women [10].
HPV vaccine acceptability is generally high in women
over 26 [11, 12] but a number of studies report a decrease
in vaccine acceptability with increasing age [13–18], which
raises the questions of whether and why older women think
the vaccine is relevant to them. Thus, this study assessed
the relevance of HPV vaccination to US women aged 27–
45 as well as their intentions regarding HPV vaccination (if
approved in the future for this age group).
2.Materialsand Methods
2.1. Study Design. This is the third of several reports on a
survey of adult women’s attitudes toward the HPV vaccine
[19, 20]. Subjects were identiﬁed using medical and phar-
macy claims from a large US managed care plan aﬃliated
with i3 Innovus. The health plan provides fully insured cov-
erageofphysician, hospital, and prescriptiondrugservices to
morethan15millionpatientsacrosstheUnitedStates.Aself-
administered survey assessed personal relevance of the HPV
vaccine and intentions regarding HPV vaccination (if oﬀered
in the future). The Copernicus Group Independent Review
Board approved the study design.2 ISRN Obstetrics and Gynecology
2.2. Study Sample. Women were identiﬁed in the health
plan database if they had an outpatient medical claim on
an index date occurring between January 1 and April 30,
2007 (the identiﬁcation period), were 27–45 years of age
on the index date, and were continuously enrolled in the
health plan during an observation period extending from
6 months before to 12 months following the index date.
Women were excluded if they had a medical claim related to
cervical cancer during the 18-month observation period or a
claim for HPV vaccination during the identiﬁcation period.
A total of 141,130 women met the above criteria. Samples
of 1,375 women were randomly selected from among those
aged 27–34 and 35–45, for a total of 2,750 study subjects.
2.3. Survey Administration. Survey packets were mailed
beginning in April 2008. Packets contained an invitation
letter, an informed consent form, a 7-page survey, and a pay-
ment of $10 as compensation for participation. the reminder
postcards were sent one week following the initial mailing,
and a second survey packet was sent to nonrespondents after
three weeks. The total survey collection period was 8 weeks.
2.4. Survey Content. The survey collected information on
demographic characteristics (age, ethnicity, educational his-
tory, marital status, and employment status), overall health
status, and general attitudes about reproductive health.
A series of questions then assessed the respondents’ attitudes
toward HPV vaccination. After being asked to read a short
paragraph about HPV, the HPV vaccine, and the types
of diseases the vaccine prevents, respondents were asked
“How relevant is this vaccine to you?” Possible answers were
“extremely relevant,” “very relevant,” “relevant,” “slightly
relevant,” and “not at all relevant.”
If the respondent indicated that the vaccine was relevant
(deﬁned as answers ranging from extremely to slightly
relevant), she was asked about her reasons for believing
so. Possible reasons included the desire for protection from
HPV and its various sequelae and beliefs about the safety
and eﬃcacy of the vaccine. Respondents who thought the
vaccine was relevant to them were asked with which type
of health care provider they would speciﬁcally discuss the
vaccine. Possible answers were “gynecologist (OB/GYN),”
“general/family practitioner (GP/FP),” “internist or internal
medicine doctor (IM),” and “nurse practitioner/physician’s
assistant.” They were also asked how likely they would be to
g e tt h ev a c c i n ei fi tw e r eo ﬀered in the future: “extremely
likely,” “likely,” “unsure,” “unlikely,” or “extremely unlikely.”
Respondents who indicated that the vaccine was not rel-
evant to them were asked why they believed it was not rele-
vant.Possibleanswers includednotbeingatriskforHPVand
its sequelae, needing more information about the vaccine,
and being married or in a monogamous relationship.
2.5. Data Analysis. A descriptive analysis was conducted on
t h ee n t i r es t u d ys a m p l e .T h er e s u l t sa r ep r e s e n t e da st h e
numberand percentageofrespondentswho gaveaparticular
answer to each survey question.Demographiccharacteristics
are given for all respondents, but the frequencies of reasons
givenforrelevanceor irrelevanceofthevaccineare presented
as a proportion of respondents in those subgroups. A strati-
ﬁed analysis of age groups 27–34 and 35–45 was carried out
to determine whether there were any attitudinal diﬀerences
between them.
3.Results
3.1. Respondent Characteristics. Of 2,750 surveys sent out,
457 were completed and returned, for an overall response
rate of 16.6%. Six respondents were subsequently found to
be ineligible due to HPV vaccination or disenrollment from
the health plan, leaving 451 surveys available for analysis.
Respondents (Table 1) were predominantly white (84.0%),
married (75.6%), and employed fulltime (67.8%). Their
mean (SD) age was 36.8 (5.4), and most (88.2%) had heard
of an HPV or cervical cancer vaccine prior to receiving the
surveypacket.Responserateswere21.4%for35–45-yearolds
and 11.4% for 27–34-year olds, so that the majority of the
study subjects (65.2%) were in the older age group (Table 1).
3.2. AttitudestowardHPVVaccination amongRespondents for
Whom the Vaccine Was Relevant. Of the 451 respondents,
304 (67.4%) reported that the HPV vaccine was relevant
to them. Among these women, the most frequent reasons
given for believing the vaccine to be relevant (Table 2)
were protection from cervical cancer(62.8%), vaginal cancer
(58.2%), precancerous cells (55.9%), and HPV (55.6%).
Concern about public health was cited by 47.0% of women
and protection against genital warts by 46.4%. A stratiﬁed
analysis of 27–34 and 35–45-year olds found no statistically
signiﬁcant diﬀerencesin their perceptions of relevance of the
vaccine.
Almost all (92.8%) women who thought the HPV
vaccine relevant would plan to discuss the vaccine with
a gynecologist (Table 3). Among women who found vacci-
nation relevant, 71.1% were likely or extremely likely to be
vaccinated if the HPV vaccine were oﬀered in the future
t ow o m e ni nt h e i ra g eg r o u p( Figure 1), while 10.1% were
unlikely or extremely unlikely to be vaccinated.
3.3. Attitudes toward HPV Vaccination among Respondents
for Whom the Vaccine Was Not Relevant. There were 143
(31.7%) respondents who felt the HPV vaccine was not
relevant to them. Among this group, the most frequently
reported reasons for HPV vaccination not being relevant
(Table 4) were being married (54.0%), being in a monog-
amous relationship (39.6%), not being at risk for HPV
(25.2%) or genital warts (19.4%), and concerns about
vaccine safety (19.4%) and eﬀectiveness (17.3%).
4.Discussion
In this insured population of women aged 27 to 45, about
two-thirds felt the HPV vaccine was relevant to them, and,
among these, nearly three in four were likely or extremely
likely to get vaccinated if HPV vaccination were oﬀered in
the future to women of their age. One-third saw the vaccineISRN Obstetrics and Gynecology 3
Table 1: Respondent characteristics.
N %
Totala 451 100
Ages 27–34 157 34.8
Ages 35–45 294 65.2
Marital status, N = 451
Married 341 75.6
Single, never married 59 13.1
Divorced 41 9.1
Separated/widowed 10 2.4
Overall health status, N = 443
Poor 3 0.7
Fair 32 7.2
Good 131 29.6
Very good 203 45.8
Excellent 74 16.7
Education, N = 450
Some high school or less 4 0.9
High school or equivalent (e.g., GED) 38 8.4
Some college, but no degree 94 20.9
Two-year degree or college graduate 227 50.4
Graduate school 87 19.3
Race/ethnicity (check all that apply), N = 451
White 378 83.8
Hispanic or Latino 30 6.7
Black/African-American 29 6.4
Otherb 105 23.3
Employment status (check all that apply),
Fulltime 306 67.8
Parttime 48 10.6
Homemaker/notemployed 78 17.3
Student 12 2.7
aMissing responses are indicated by the Ns for each response category.
bAmerican Indian, Alaska Native, Asian, Native Hawaiian, Paciﬁc Islander,
and Other.
as not relevant, most commonly because they were married
or in a monogamous relationship or because they believed
thattheywereatlowriskforgettingHPVinfectionandHPV-
related disease.
Only one othersurvey hasspeciﬁcally elicitedthe reasons
older women have for wanting or not wanting the HPV
vaccine [13, 21]. In the ﬁrst of two reports on that survey,
the most frequent reasons for wanting the HPV vaccine were
adesire tostay healthy(48.9%),preventionofcervicalcancer
(42.8%), and prevention of genital warts (33.5%) [21]. The
most common reasons for not wanting the vaccine were
beinginamonogamousrelationship(29.5%)andperception
oflowriskofHPVinfection(15.0%).Inthesecondandmore
quantitative report, women in a monogamous relationship
had half the odds (OR 0.46) of wanting the HPV vaccine,
while women who felt at risk for HPV infection had higher
odds of wanting the vaccine (OR 2.14) [13].
Table 2: Reasons for relevance of HPV vaccination.a
N %
I want to be protected from cervical cancer 191 62.8
I want to be protected from vaginal cancer 177 58.2
I want to be protected from precancerous cells 170 55.9
I want to be protected from getting HPV 169 55.6
It is the right thing to do for public health (stop the
spread of HPV) 143 47.0
I want to be protected from genital warts 141 46.4
It is better to have the vaccine than to not have it 127 41.8
This vaccine is safe 82 27.0
This vaccine is eﬀective 75 24.7
I am not in a monogamous relationship 11 3.6
Other 82 27.0
aTotal N = 304. Relevance was deﬁned as responses of slightly relevant,
relevant, very relevant, or extremely relevant. Respondents were instructed
to “check all that apply.”
Examples include having personal or family history of HPV infection or
cervical disease or having one or more daughters to protect against HPV-
related disease.
Table 3: Types of health care providers with whom respondents
would discuss the HPV vaccine.a
N %
Gynecologist (OB/GYN) 282 92.8
General/family practitioner (GP/FP) 105 34.5
Nurse practitioner/physician’s assistant 49 16.1
Internist or internal medicine doctor (IM) 28 9.2
Other 14 4.6
aAmong respondents who considered the HPV vaccine relevant. Total N =
304. Respondents were instructed to “check all that apply”.
Example: daughter’s pediatrician.
Younger women have similar reasons for wanting or not
wanting the HPV vaccine. Belief in the severity of cervical
cancer was associated with higher intent to be vaccinated
among 13–26-year olds [22], and knowledge of HPV and its
relationship to cervical cancer has been found to correlate
with vaccine acceptability in young adult women [14, 23].
Similarly, among nonvaccinees in this age range, a frequent
reason for inaction regarding HPV vaccination is being
married or in a monogamous relationship [19]. Other
reasons for inaction or lack of interest are also common
and include a perceived lack of need, usually due to sexual
inactivity or low risk, and concerns about the safety of the
vaccine [24, 25].
In previous studies of nonvaccinees, 7 to 14.6% of
women aged 18–26 cited cost as a reason for not being
vaccinated [19, 25]. Cost was also a barrier reported by
college women who had chosen not to receive the vaccine
[26]. However, in this survey of women over 26, fewer than
1.0% of the total number of respondents expressed concerns
regarding aﬀordability. This was perhaps because they all
had insurance coverage—a similar study of a nationally
representative sample of US women aged 27–55 found
that cost was the most inﬂuential factor in HPV vaccine4 ISRN Obstetrics and Gynecology
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Figure 1: Likelihood of getting the HPV vaccine if oﬀered in the
future (among respondents for whom the vaccine was relevant
(N = 304)).
Table 4: Reasons why HPV vaccination is not relevant.a
N %
I am married 75 54.0
I am in a monogamousrelationship (one partner at
at i m e ) 55 39.6
I am not at risk for getting HPV 35 25.2
I am not at risk for getting genital warts 27 19.4
I am not convinced/need more informationon the
vaccine’s safety 27 19.4
I am not convinced/need more informationon the
vaccine’s eﬀectiveness 24 17.3
I am not at risk for getting cervical cancer 14 10.1
I am not at risk for getting vaginal cancer 7 5.0
I do not currently have sexual relations 7 5.0
I cannot aﬀord this vaccine 2 1.4
Other 62 44.6
aFour of the 143 respondents who reported that the vaccine was not at
all relevant did not answer this question, leaving 139 total responses from
which to calculatethe percentagesshown here. Respondents wereinstructed
to “check all that apply.”
Examples include outside of indicated age range (i.e., >age 26), having
personal history of HPV infection or cervical disease.
acceptability across multiple sociodemographic and health
variables [12].
Awareness of HPV and the HPV vaccine is generally high
in women over 26. The National Immunization Survey of
2007 found that 82.9% of US women aged 27–48 had heard
of HPV and 76.5% had heard of the HPV vaccine (versus
88.6% and 82.8%, resp., of women aged 18–26) [25]. In
Canada, 84.7% of adult women (mean age 33) surveyed in
2007 indicated that they had heard of HPV, though only
39.8% had heard of the HPV vaccine [15]. Most respondents
in this study (88.2%) had heard of an HPV or cervical cancer
vaccine prior to receiving the survey packet. Although HPV
awareness was lower (<60%) in 2005-2006 in some rural
regions of the United States [18, 27], it can be expected
to increase over time as HPV vaccination becomes more
common.
Health care providers are women’s most trusted source
of information about HPV and the HPV vaccine [28, 29].
In fact, physician discussion and recommendation are im-
portant predictors of vaccination in younger women [20, 25,
29, 30]. One recent survey suggests that physicians may also
be inﬂuential for women aged 27–45: among women in this
age group who were not aware of the vaccine or who had
not received a physician’s recommendation, 80% reported
that they would get vaccinated if a health care provider
recommended it [25].
Physician recommendation may play an especially
important role for married women, who in both younger
and olderadult age groups feel less at risk for HPV infection.
Their perception is supported by prevalence data showing
that HPV infection is twice as likelyin never married women
and three times as likely in widowed/divorced/separated
or cohabiting women compared to married women [4].
Nevertheless, HPVinfection isstill prevalent(17.3%)among
married women [4], and our previous analysis showed
physician recommendation to be a stronger predictor of
vaccination than marital status [20].
Because the prevalence of HPV peaks among women
aged 20–24 [4], one question of particular relevance to
older women is whether vaccination can prevent HPV-
related disease in previously exposed or currently infected
individuals. Clinical studies have shown that, in women
infected with some, but not all, of the four HPV types
targeted by the quadrivalent vaccine, the vaccine prevented
disease causedbytheremaining HPV types[31].Preliminary
ﬁndings are similar for the bivalent vaccine [32]. Another
question is whether older women are at risk for acquiring
new HPV infections. Studies conducted in several countries
indicate that, while incidence of HPV infection declines in
the fourth decade compared to earlier ages, there remains a
signiﬁcant risk of HPV infection in sexually active women
of all ages [32]. In Canada, for instance, the one-year
acquisitionrateofoncogenicHPVinfectionwas9.7%among
women aged 25–49 [33]. Furthermore, a large cohort study
in Costa Rica found that type-speciﬁc persistence increases
with age, particularly for HPV-16 [34].
One limitation of our study was the low survey response
r a t e .W ew e r ea b l et oc o m p a r et h ea g ea n dg e o g r a p h i cl o c a -
tions of respondents and nonrespondents using claims data.
There were no statistically signiﬁcant diﬀerences between
these two groups in age, whether analyzed as a continuous
variable or as a categorical variable (age categories 27 to
35 and 36 to 45 years). Similar proportions of respondents
and nonrespondents resided in the Northeast and West, but
respondents were more likely than nonrespondents to be
located in the Midwest (32.6% versus 24.8%, P<. 001)
and less likely to reside in the South (46.1% versus 55.6%,
P<. 001). It is possible that this geographic imbalance
may have produced bias in the estimation of reports of
HPV vaccine relevance. In addition, respondents were given
limitedinformation ontheeﬃcacyofthevaccine,whichmay
have aﬀected their perceptions of relevance. Because of the
studypopulationchosen,theresultsmaynotbegeneralizable
to women living outside the United States or women without
health insurance. Finally, intention to getvaccinated may notISRN Obstetrics and Gynecology 5
translate into actual uptake [35], so the interpretation of the
results pertaining to future action is limited.
5.Conclusions
In this sample of women aged 27 to 45, most felt the
HPV vaccine was relevant to them because of its ability to
protect them from HPV infection and HPV-related diseases.
The majority of women reporting relevance were likely to
consider vaccination if the vaccine became available to their
age group. Women who did not feel the vaccine was relevant
did not perceive themselves at risk for HPV infection or
HPV-related diseases.
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